Breaking News Bar
updated: 10/26/2012 10:48 AM

Merck 3Q profit up 2 pct despite sales decline

hello
Success - Article sent! close
  • Drugmaker Merck & Co. said Friday, Oct. 26, 2012 that third-quarter profit rose 2 percent as reduced spending on overhead offset lower sales due to new generic competition for its top-selling drug. The company beat Wall Street's profit expectations and narrowed its 2012 profit forecast, to a range of $2.08 to $2.24 per share, from its July forecast of $2.04 to $2.30.

      Drugmaker Merck & Co. said Friday, Oct. 26, 2012 that third-quarter profit rose 2 percent as reduced spending on overhead offset lower sales due to new generic competition for its top-selling drug. The company beat Wall Street's profit expectations and narrowed its 2012 profit forecast, to a range of $2.08 to $2.24 per share, from its July forecast of $2.04 to $2.30.
    ASSOCIATED Press

 
Associated Press

Drugmaker Merck & Co. said Friday that third-quarter profit rose 2 percent as reduced spending on overhead offset lower sales due to new generic competition for its top-selling drug, Singulair.

The maker of diabetes pill Januvia beat Wall Street's profit expectations. The company also narrowed its 2012 profit forecast, to a range of $2.08 to $2.24 per share, from its July forecast of $2.04 to $2.30.

Order Reprint Print Article
 
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.
Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Success - request sent close

Merck, based in Whitehouse Station, N.J., said net income was $1.73 billion, or 56 cents per share. That was up from $1.69 billion, or 55 cents per share, a year earlier.

Excluding charges totaling $1.2 billion, net income was $2.93 billion, or 95 cents per share, 2 cents more than analysts expected. Charges included $1.34 billion in acquisition and integration costs, plus $163 million in restructuring costs.

Revenue was $11.5 billion, down 4 percent. Analysts expected $11.57 billion.

Sales of asthma and allergy pill Singulair dove 55 percent, to $602 million.

Strong global sales offset the impact of Singulair's U.S. patent expiring on Aug. 3, CEO Kenneth Frazier said in a statement. The drug brought Merck $5.5 billion in sales last year.

Like nearly all big drugmakers that have reported third-quarter results, Merck has been hit by new generic competition to a top seller, as patients and insurance plans defect almost overnight to the much-cheaper copycat drugs. But Merck has fared better than most, with only a small drop in total revenue and slightly higher profit.

That's because four Merck growth drivers posted sales increases of at least 15 percent: Januvia and combination diabetes pill Janumet, HIV drug Isentress and Gardasil, a vaccine against sexually transmitted cancers caused by human papilloma virus. Januvia and Janumet together brought in nearly $1.4 billion.

In addition, the company reduced spending on production, marketing, administration and research, and also benefited from lower taxes.

Prescription drug sales totaled $9.88 billion, down 5 percent. But consumer health products, including the Coppertone sun-care line and Dr. Scholl's foot-care products, saw sales climb 7 percent to $451 million. Sales of veterinary medicines dipped 1 percent to $815 million.

"With our robust pipeline, we remain on target to submit multiple new products for marketing approval between now and the end of 2013," Frazier said.

Those include suvorexant, a new type of insomnia drug with minimal morning grogginess, and vorapaxar, an anti-clotting drug for preventing heart attacks and strokes in certain patients. Others include osteoporosis drug odanacatib, cholesterol medicine Tredaptive, ovarian and lung cancer drug vintafolide, a drug to reverse the effects of anesthesia called Bridion and an improved version of Gardasil.

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.
    help here